BIRC5 is a well-known biomarker for tumor progression as it promotes cell proliferation and overall rates of survival and is associated with poor clinical outcome in patients with acute myeloid leukemia (AML) [45,46]. This evidence concerns the gene BIRC5 and acute myeloid leukemia.